Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Karin Van, Baelen"'
Autor:
Khyati Roberts, Roopal Thakkar, Lina Aljuburi, Donna Boyce, Sean Curtis, Jennifer Dudinak, Helen Fitton, Carlos Garner, Michael Garvin, Susan Longman, Edward Reilly, Jordan Maitland, Alexis Reisin Miller, Muriel Pasté, Michelle Rohrer, Mark Taisey, Karin Van Baelen, Max Wegner
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 6, Pp 1321-1327 (2022)
Externí odkaz:
https://doaj.org/article/101581f4da4943ee986adb99812432af
Autor:
Agnese Cangini, Maren Koban, Leonor Varela Lema, Spiros Vamvakas, Deborah Morrison, Sonia Garcia, Solange Corriol-Rohou, Emmanuel Gimenez Garcia, Anders Viberg, Piia Rannanheimo, Muriel Pasté, Alison Cave, Catherine Cohet, Peter Arlett, Xavier Kurz, Susan Sandler, Mercè Obach, Amr Makady, Hanna-Mari Jauhonen, Michael Berntgen, Virginia Acha, Emma Du Four, Jane Moseley, Karin Van Baelen, Chantal Guilhaume, Anja Langeneckert, Anna Strömgren, Marc Van De Casteele, Christelle Lamoril, Simon Bennett
Publikováno v:
British Journal of Clinical Pharmacology
The understanding of the benefit risk profile, and relative effectiveness of a new medicinal product, are initially established in a circumscribed patient population through clinical trials. There may be uncertainties associated with the new medicina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e141d17c08674af1e55a0c7de8b1f744
https://doi.org/10.1111/bcp.14279
https://doi.org/10.1111/bcp.14279
Autor:
Susan Berger, Robert Kowalski, Michael Garvin, Deborah Autor, Sandra Milligan, Roopal Thakkar, Carlos Garner, Mark Taisey, Mathias Hukkelhoven, Max Wegner, Peter Honig, Lina AlJuburi, Liza O’Dowd, Khyati Roberts, Helen Fitton, Jerry Stewart, Karin Van Baelen, Edward Reilly, Patrick Brady, Andrew S. Robertson
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1390-1392
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf141f244368d14c909d0ac26449c187
https://doi.org/10.1002/cpt.2046
https://doi.org/10.1002/cpt.2046
Autor:
Mark Taisey, Peter Honig, Carlos Garner, Sharon Olmstead, Andrew S. Robertson, Robert Kowalski, Karin Van Baelen, Michelle Rohrer, Khyati Roberts, Liza O’Dowd, Jerry Stewart, Michael Garvin, Max Wegner, Sandra Milligan, Edward Reilly, Roopal Thakkar, Helen Fitton, Mathias Hukkelhoven, Fabio Bisordi, Deborah Autor
Publikováno v:
Clinical pharmacology and therapeutics. 108(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a40a59f0b7e552ea3978d03599e3675
https://pubmed.ncbi.nlm.nih.gov/32337707
https://pubmed.ncbi.nlm.nih.gov/32337707
Autor:
Murray Lumpkin, Mark R. Trusheim, Gigi Hirsch, Richard Bergstrom, Pamela Gavin, Nathalie Seigneuret, Anton Hoos, Magda Chlebus, Michel Goldman, Karin Van Baelen, Duane Schulthess, Lynn G. Baird, Sarah Garner, Thomas F. Unger
Publikováno v:
Therapeutic innovationregulatory science. 50(3)
After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0779b5e220d87c761d1b6702f4d8c2
https://pubmed.ncbi.nlm.nih.gov/30227070
https://pubmed.ncbi.nlm.nih.gov/30227070
Autor:
Max Wegner, Helen Fitton, Robert Kowalski, Peter Honig, Michelle Rohrer, Khyati Roberts, Roopal Thakkar, Mathias Hukkelhoven, Mark Taisey, Hilary Malone, Stacy Holdsworth, Andrew S. Robertson, Sandra Milligan, Carlos Garner, Liza O’Dowd, Jerry Stewart, Karin Van Baelen, Fabio Bisordi
Publikováno v:
Nature Reviews Drug Discovery. 19:365-366
Cloud-based systems for data submitted by sponsors to drug regulatory agencies have the potential to accelerate drug development, streamline regulatory review and enhance regulatory decision-making. Here, we provide a vision for integrating cloud-ena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6eca4e9f9078172d4ade4d94780b51c
https://doi.org/10.1038/d41573-019-00193-7
https://doi.org/10.1038/d41573-019-00193-7
Publikováno v:
Chinese clinical oncology. 3(2)
Eroom's Law is, literally, Moore's law in reverse. The pharmaceutical sector invests $50 billion annually in research for new medicines but, "the number of new drugs approved per billion US dollars spent has halved roughly every 9 years since 1950, f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::929e20d99c39381b020a97b830af10fc
https://pubmed.ncbi.nlm.nih.gov/25841417
https://pubmed.ncbi.nlm.nih.gov/25841417